StreetAlpha.app
Home › Stocks › LUCD

Lucid Diagnostics Inc. (LUCD)

$0.40
▲ +0.30%
LAST CLOSE · NOV 17

Lucid Diagnostics makes EsoGuard, a DNA test that screens for precancerous changes in the esophagus in people with chronic heartburn. It last closed at $0.40 on Nov 17, up 0.30% on the day. The average 12-month price target from 2 analysts is $6.00 (+1403.8% from the last close), with a high of $9.50 and a low of $2.50.

AI Auto Pilots
Is LUCD in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$5.4M
+23.6% vs a year ago
Net income
−$48.5M
−892.9% margin
EPS (diluted)
−$0.36
Free cash flow
−$51.8M
−953.5% margin
Valuation
Market cap
$82.6M
207.0M shares
P/E
–
No P/E while losing money
Price to sales
15.2
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Shareholder equity
$5.9M
Shares outstanding
207.0M
At Nov 10
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $500K$500KFY2021FY2022: $377K$377KFY2022FY2023: $2.4M$2.4MFY2023FY2024: $4.3M$4.3MFY2024FY2025: $4.7M$4.7MFY2025

From LUCD's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Last report
Nov 12
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated LUCD in the past 90 days, not enough for a consensus
Average 12-month target
$6.00
▲ 1403.8% upside

Based on 2 analysts who set a price target on LUCD in the past 90 days. The average target is $6.00, with a high of $9.50 and a low of $2.50, compared with the last close of $0.40.

Low $2.50Avg $6.00High $9.50
Blue marker: last close $0.40
Highest target$9.50
Average target$6.00
Lowest target$2.50
Latest rating changes
BTIGReiterated
Oct 23Buy$2.50
Ascendiant CapitalTarget raised
Aug 27Buy$9.25 → $9.50
Ascendiant CapitalMaintained
Jun 8Buy$9.25
DateFirmActionRatingPrice target
Oct 23BTIGReiteratedBuy$2.50
Aug 27Ascendiant CapitalTarget raisedBuy$9.25 → $9.50
Jun 8Ascendiant CapitalMaintainedBuy$9.25
Loading…

Technical Analysis

LUCD · as of the Nov 17 close · updated after every close
Downtrend

The stock is 3% below its 20 day and 45% below its 50 day average. It is 145% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 42). The nearest support is the Pivot at $0.39, and the nearest resistance the Pivot R1 at $0.41.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 14.4%/day
Key levels
$1.6352 week high+307.5%
$0.98200 day average+145.0%
$0.78100 day average+95.0%
$0.5850 day average+45.0%
$0.48Swing high (Nov 4)+20.0%
$0.4120 day average+2.5%
$0.41Pivot R1+2.5%
$0.40Last close
$0.39Pivot−2.5%
$0.38Pivot S1−5.0%
$0.38Swing low (Oct 28)−5.0%
$0.3052 week low−25.0%
Indicators
RSI (14)41.69Middle of its rangeNeutral
MACD-0.05Above its signal lineBullish
Stochastic30.7Middle of its rangeNeutral
ADX (14)15.9No clear trend
Williams %R-76.3Oversold below −80, overbought above −20Neutral
CCI (20)-59.2Oversold below −100, overbought above 100Neutral
Rate of change−4.3%Change over 10 sessionsBearish
ATR (14)$0.06Typical daily range, 14.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for LUCD

What happened before

See how LUCD did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow LUCD usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How LUCD has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in LUCD in the last 90 days.

Loading…

See today’s whale options flow across the market →

LUCD Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●46 buying vs 48 selling
  • ▼Held by funds -0.5 pts
  • ●Funds holding -1
  • ●Superinvestors: 1 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding115116−0.9%
In funds' top 1000–
Held by funds29.1%29.7%−0.5 pts
New / increased15 / 3125 / 59−45.2%
Reduced / sold out31 / 1712 / 10+118.2%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See LUCD institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LUCD is in one of them and how their past LUCD trades turned out.

LUCD in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered LUCD in an article yet. Here's the latest on the wider market.

About Lucid Diagnostics

Lucid Diagnostics is a medical diagnostics company based in New York. Its main product is EsoGuard, a DNA test that looks for precancerous changes in the esophagus, run on cell samples collected with the EsoCheck swallowable capsule device. The company targets people with chronic heartburn, also known as GERD, who are at risk of esophageal cancer, and it offers testing through its own test centers, mobile units, physician office programs and health system arrangements.

Headquarters
New York, NY